SA PRO
Free Account
Aclaris Therapeutics, Inc.ACRSNASDAQ
LOADING
|||
OverviewChartsNewsFundamentalsEarningsAnalysts

Earnings & Revenue Estimates

Earnings Surprises

Recent Analyst Actions

Jan 30, 2026Craig-Hallum
Craig-Hallum bullish on Aclaris Therapeutics, initiates with a Buy
Target:$10.00
+191.5%from $3.43
Nov 19, 2024BTIG
BTIG Upgrades Aclaris Therapeutis (ACRS) to Buy
Target:$8.00
+154.8%from $3.14
Nov 19, 2024Jefferies
Jefferies Upgrades Aclaris Therapeutis (ACRS) to Buy
Target:$7.00
+122.9%from $3.14
Nov 6, 2024Stifel Nicolaus
Aclaris Therapeutis (ACRS) PT Raised to $3 at Stifel
Target:$3.00
+31.9%from $2.27
Dec 1, 2022Goldman Sachs
Goldman Sachs Initiates Coverage On Aclaris Therapeutics with Buy Rating, Announces Price Target of $25
Target:$25.00
+64.3%from $15.22

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance